Arbutus Biopharma market cap ABUS
Share price times shares outstanding: what the whole company sells for, since 2012.
- Today, Nov 2, 2026
- $791.4M
- Highest close in our data
- $1B
- Aug 2026
Arbutus Biopharma is worth $791.4M at the close on Nov 2, 2026, at $4.00 a share.
That is down 8% over the last year and up 68% over five years.
Its highest close in our data was $1B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $791.4M | $738.5M | $1B | −14% |
| 2025 | $919.3M | $589.9M | $919.3M | +51% |
| 2024 | $608.3M | $387.4M | $859M | +45% |
| 2023 | $419.2M | $289.9M | $492.6M | +15% |
| 2022 | $364.6M | $286.4M | $473.4M | −31% |
| 2021 | $526.2M | $252.5M | $579M | +75% |
| 2020 | $301.4M | $62.7M | $369.4M | +113% |
| 2019 | $141.6M | $50M | $253.5M | −34% |
| 2018 | $215.3M | $194.7M | $644.1M | −23% |
| 2017 | $278M | $139.8M | $398.9M | +107% |
| 2016 | $134.4M | $134.4M | $291.2M | −45% |
| 2015 | $242.8M | $242.8M | $907.1M | −23% |
| 2014 | $315.9M | $111.6M | $652.8M | +184% |
| 2013 | $111.3M | $52.8M | $138.2M | +90% |
| 2012 | $58.4M | $23.7M | $63.4M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Arbutus Biopharma's size, closest first, today.
| Company | Market cap |
|---|---|
| ABUSArbutus Biopharma | $791.4M |
| COLLCollegium Pharmaceutical | $770.9M |
| ZVRAZevra Therapeutics | $599.8M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| PBYIPuma Biotechnology | $525.5M |
| ARVNArvinas | $491.7M |
| OMEROmeros | $1.3B |
| ANABAnaptysbio | $1.4B |
| PCRXPacira BioSciences | $1.5B |
| CRMDCorMedix | $420.1M |
| Peer median | $685.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Arbutus Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.